Skip to main content
OpenTrials
Completed

NCT Number: NCT00560768

Predictive Risk Stratification Through T Variability in ICD Patients Without Pacing Indications

The aim of the study is to assess the negative predictive value of the T amplitude variance as a method for risk stratification for patients with an increased risk for SCD.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Grey-Nuns Hospital, Edmonton, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patient has been prescribed the implantation of an SORIN GROUP OvatioTM DR 6550 / VR 6250 system according to relevant currently-approved guidelines

  • CHF since > 3 months and
  • LVEF < 35% and
  • NYHA class II or III

OR

  • Prior Myocardial infarction since more than 4 weeks and
  • LVEF < 30%

Exclusion criteria

  • Documented spontaneous sustained ventricular tachycardia
  • Prior implant of any device for ventricular cardiac pacing
  • Existing indication for permanent ventricular pacing
  • Myocardial infarction within 4 weeks prior to enrollment
  • Arrhythmogenic RV-Dysplasia
  • Brugada syndrome
  • Long QT syndrome
  • Performed within 3 months prior to enrollment or scheduled (within 3 months) cardiac revascularization (interventional or surgical)
  • Any indication for CRT accordingly to the relevant currently-approved ACC/AHA1 or ESC35 guidelines for the implantation of a CRT system.
  • Excisting or planned administration of amiodarone - initiation of amiodarone therapy during the run of the study will lead to immediate exclusion of the patient
  • Permanent chronic atrial fibrillation / flutter
  • Patient is unable to attend the scheduled follow-up visits at the participating centre
  • Patient is already included in another ongoing clinical study
  • Patient is unable to understand the objectives of the study
  • Patient refuses to cooperate
  • Patient is unable or refuses to provide informed consent
  • Patient is minor (less than 18-year old)
  • Patient has life expectancy of less than 1 year
  • Patient is pregnant.

Treatment and study plan

Ovatio VR 6250 or DR6550

Device

The study requires the implantation of locally approved material:

  • A right ventricular defibrillation lead
  • In case of use of a dual chamber ICD a right atrial pacing lead
  • A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.

Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar.

Primary outcomes

  1. TAV score and number of tachyarrhythmic events.

    Time frame: The two phases M0 - M12 and M12 - M24 will be examined separately. For each 12 months period the TAV score at its beginning and tachyarrhythmic events in the following 12 months will be assessed. The NPV will be calculated for both phases.

Secondary outcomes

  1. TAV change

    Time frame: 12 months of follow up

Sponsors and collaborators

Lead sponsor

LivaNova

Industry

Registry information

Acronym: Prediction

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
Nov 20, 2007
Registry last updated
Jan 12, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.